ArticleBiomaterials research2026
Construction of a Bioactive ECM Interface Enables Concurrent Suppression of Foreign Body Reaction, Inflammation, and Promotion of Urethral Regeneration.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of tissue-engineered urethral grafts (TEUGs) remains challenged by significant hurdles, particularly in overcoming intraurethral stricture. A core issue is the foreign body reaction (FBR) induced by the implant, which impairs the integration of TEUGs with the autologous urethra. This study employed a tissue-engineered cellularization strategy to construct a stable, hydrophilic, and elastic bioactive extracellular matrix (ECM) interface on the scaffold surface. This interface effectively resists FBR and enhances TEUG integration with host tissues. We developed an "autologous" cellularized TEUG by combining rabbit-derived smooth muscle cells and endothelial cells with nanofiber scaffolds in vitro. After seeding, the cells attached to the scaffold, synthesized, and deposited ECM, thereby fine-tuning the scaffold's biophysical and biochemical properties. Specifically, glycosaminoglycans (GAGs) in the ECM enhanced scaffold hydrophilicity, while collagen and elastin regulated its elasticity. In a rabbit model of full-thickness urethral defect, GAGs in TEUGs induced a pro-regenerative immune response, characterized by up-regulated expression of arginase 1, CCAAT/enhancer-binding protein β, and tissue inhibitor of metalloproteinase 1 genes and down-regulated expression of matrix metalloproteinase 9 and interleukin-12 genes. This M2 macrophage-dominated gene expression profile further activated the Th2 signaling pathway, promoting the reconstruction of damaged vascular networks, the ordered proliferation of new tissues, the replacement of original ECM, load transmission in new tissues, and the maturation of functional structures. This study provides a simple yet effective strategy to enhance the patency, urine transport capacity, synchronous contraction, and directional contractile function of TEUGs by engineering a bioactive ECM interface endowed with anti-inflammatory and anti-FBR properties.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.